Gene,uniprot_id,Orig_AA,Position,Mutated_AA,X6
ALK,Q9UM73,F,1174,L,"/note=""F -> L (in NBLST3; somatic mutation; constitutively activated; retained in the endoplasmic reticulum and Golgi compartments; dbSNP:rs863225281)"" /evidence=""ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:18923525, ECO:0000269|PubMed:21242967"" /id=""VAR_063857"""
ALK,Q9UM73,F,1174,V,"/note=""F -> V (in NBLST3; somatic mutation; constitutively activated; retained in the endoplasmic reticulum and Golgi compartments; dbSNP:rs281864719)"" /evidence=""ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:21242967"" /id=""VAR_063858"""
ALK,Q9UM73,R,1275,Q,"/note=""R -> Q (in NBLST3; constitutively activated; retained in the endoplasmic reticulum and Golgi compartments; dbSNP:rs113994087)"" /evidence=""ECO:0000269|PubMed:18724359, ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:18923525, ECO:0000269|PubMed:21242967"" /id=""VAR_063865"""
BRAF,P15056,R,671,K,"/note=""R->K: Increased kinase activity and stability in response to EGF treatment."" /evidence=""ECO:0000269|PubMed:21917714"""
EGFR,P00533,E,709,G,"/note=""E -> G (found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild- type; dbSNP:rs397517085)"" /evidence=""ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628"" /id=""VAR_069498"""
EGFR,P00533,G,719,S,"/note=""G -> S (found in a lung cancer sample; somatic mutation; strongly increased kinase activity; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild- type; dbSNP:rs28929495)"" /evidence=""ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580"" /id=""VAR_019297"""
EGFR,P00533,S,768,I,"/note=""S -> I (found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild- type; dbSNP:rs121913465)"" /evidence=""ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628"" /id=""VAR_069502"""
EGFR,P00533,T,790,M,"/note=""T -> M (found in a lung cancer sample; increased kinase activity; dbSNP:rs121434569)"" /evidence=""ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:18227510"" /id=""VAR_026098"""
EGFR,P00533,L,858,R,"/note=""L -> R (found in a lung cancer sample; somatic mutation; constitutively activated enzyme with strongly increased kinase activity; more sensitive to gefitinib than wild-type; dbSNP:rs121434568)"" /evidence=""ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580"" /id=""VAR_019298"""
EGFR,P00533,L,861,Q,"/note=""L -> Q (found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild- type; dbSNP:rs121913444)"" /evidence=""ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793"" /id=""VAR_026102"""
EGFR,P00533,D,587,A,"/note=""D->A: Increased EGF binding; when associated with A- 590 and A-609."" /evidence=""ECO:0000269|PubMed:19718021"""
EGFR,P00533,H,590,A,"/note=""H->A: Increased EGF binding; when associated with A- 587; A-590 and A-609."" /evidence=""ECO:0000269|PubMed:19718021"""
EGFR,P00533,K,609,A,"/note=""K->A: Decreases intramolecular interactions and facilitates EGF binding. Increased EGF binding; when associated with A-587; A-590 and A-609."" /evidence=""ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:19718021"""
EGFR,P00533,V,689,M,"/note=""V->M: Constitutively activated kinase."" /evidence=""ECO:0000269|PubMed:19560417"""
EGFR,P00533,T,693,A,"/note=""T->A: Increased phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417"""
EGFR,P00533,E,1005,R,"/note=""ED->RK: Constitutively activated kinase."" /evidence=""ECO:0000269|PubMed:19563760"""
EGFR,P00533,D,1006,K,"/note=""ED->RK: Constitutively activated kinase."" /evidence=""ECO:0000269|PubMed:19563760"""
FGFR1,P11362,Y,374,C,"/note=""Y -> C (in OGD; elevated basal activity and increased FGF2-mediated activity; dbSNP:rs121909631)"" /evidence=""ECO:0000269|PubMed:15625620"" /id=""VAR_030993"""
FGFR1,P11362,N,546,K,"/note=""N -> K (in ECCL; somatic mutation; activating mutation; strongly increased speed of the first autophosphorylation and loss of the normal sequential order of autophosphorylation; dbSNP:rs779707422)"" /evidence=""ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:26942290"" /id=""VAR_075853"""
FGFR4,P22455,G,388,R,"/note=""G -> R (in cancer cells, may be associated with accelerated disease progression and increased tumor cell motility, possibly due to increased stability of the protease MMP14; leads to phosphorylation at residue Y-390, resulting in prolonged FGFR4 activity; increases interaction with STAT3, resulting in STAT3 phosphorylation and signaling activation.; dbSNP:rs351855)"" /evidence=""ECO:0000269|PubMed:11781352, ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:18756523, ECO:0000269|PubMed:20876804, ECO:0000269|PubMed:21349172, ECO:0000269|PubMed:21882254, ECO:0000269|PubMed:26675719, ECO:0000269|Ref.8"" /id=""VAR_014797"""
FLT3,P36888,D,835,E,"/note=""D -> E (in acute lymphoblastic leukemia patients and acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913487)"" /evidence=""ECO:0000269|PubMed:11290608, ECO:0000269|PubMed:14504097"" /id=""VAR_065679"""
FLT3,P36888,D,835,H,"/note=""D -> H (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488)"" /evidence=""ECO:0000269|PubMed:11290608, ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"" /id=""VAR_065680"""
FLT3,P36888,D,835,N,"/note=""D -> N (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488)"" /evidence=""ECO:0000269|PubMed:11290608"" /id=""VAR_065681"""
FLT3,P36888,D,835,V,"/note=""D -> V (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121909646)"" /evidence=""ECO:0000269|PubMed:11290608"" /id=""VAR_065682"""
FLT3,P36888,D,835,Y,"/note=""D -> Y (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated; dbSNP:rs121913488)"" /evidence=""ECO:0000269|PubMed:11290608, ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"" /id=""VAR_065683"""
FLT3,P36888,Y,589,F,"/note=""Y->F: Reduced phosphorylation of the wild-type kinase in response to ligand binding. No effect on the phosphorylation of the constitutively activated mutant kinase variants. Abolishes activation of STAT5A."" /evidence=""ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:16684964, ECO:0000269|PubMed:9737679"""
KIT,P10721,D,816,F,"/note=""D -> F (in MASTC; sporadic case; somatic mutation; requires 2 nucleotide substitutions; constitutively activated and is much more rapidly autophosphorylated than wild type)"" /evidence=""ECO:0000269|PubMed:9990072"" /id=""VAR_033133"""
KIT,P10721,D,816,H,"/note=""D -> H (in a testicular tumor; seminoma; somatic mutation; constitutively activated; dbSNP:rs121913506)"" /evidence=""ECO:0000269|PubMed:10362788, ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:20147452"" /id=""VAR_033134"""
KIT,P10721,D,816,I,"/note=""D -> I (in MASTC; somatic mutation; constitutively activated; requires 2 nucleotide substitutions; dbSNP:rs1057519709)"" /evidence=""ECO:0000269|PubMed:19865100"" /id=""VAR_081064"""
KIT,P10721,D,816,V,"/note=""D -> V (in MASTSYS, MASTC and mast cell leukemia; somatic mutation; constitutively activated; loss of interaction with MPDZ; dbSNP:rs121913507)"" /evidence=""ECO:0000269|PubMed:11018522, ECO:0000269|PubMed:17595334, ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:19865100, ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:7691885, ECO:0000269|PubMed:9990072"" /id=""VAR_004109"""
KIT,P10721,D,816,Y,"/note=""D -> Y (in MASTSYS and MASTC; also found in acute myeloid leukemia and a germ cell tumor of the testis; somatic mutation; constitutively activated; dbSNP:rs121913506)"" /evidence=""ECO:0000269|PubMed:16175573, ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19865100, ECO:0000269|PubMed:9657776, ECO:0000269|PubMed:9990072"" /id=""VAR_023828"""
KIT,P10721,N,822,I,"/note=""N -> I (in MASTC; constitutively activated; dbSNP:rs993022333)"" /evidence=""ECO:0000269|PubMed:21689725"" /id=""VAR_081065"""
MAP2K1,Q02750,K,57,N,"/note=""K -> N (in MEL; somatic mutation; results in increased MAPK signal transduction; dbSNP:rs869025608)"" /evidence=""ECO:0000269|PubMed:29643386"" /id=""VAR_084454"""
MAP2K2,P36507,P,128,Q,"/note=""P -> Q (in CFC4; results in increased kinase activity; dbSNP:rs267607230)"" /evidence=""ECO:0000269|PubMed:20358587"" /id=""VAR_069782"""
PDGFRA,P16234,Y,555,C,"/note=""Y -> C (in GISTPS; increased platelet-derived growth factor alpha-receptor activity; constitutively activated kinase; dbSNP:rs121908589)"" /evidence=""ECO:0000269|PubMed:17087943"" /id=""VAR_083158"""
PDGFRA,P16234,V,561,D,"/note=""V -> D (in a GIST sample; constitutively activated kinase; dbSNP:rs121908586)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066462"""
PDGFRA,P16234,H,650,Q,"/note=""H -> Q (in a hypereosinophilic syndrome sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:21224473"" /id=""VAR_066465"""
PDGFRA,P16234,N,659,K,"/note=""N -> K (in GIST sample; constitutively activated kinase; dbSNP:rs1057519700)"" /evidence=""ECO:0000269|PubMed:15928335"" /id=""VAR_066466"""
PDGFRA,P16234,N,659,S,"/note=""N -> S (in a hypereosinophilic syndrome sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:21224473"" /id=""VAR_066467"""
PDGFRA,P16234,R,748,G,"/note=""R -> G (in a hypereosinophilic syndrome sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:21224473"" /id=""VAR_066469"""
PDGFRA,P16234,D,842de,l,"/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066470"""
PDGFRA,P16234,I,843de,l,"/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066470"""
PDGFRA,P16234,M,844de,l,"/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066470"""
PDGFRA,P16234,H,845de,l,"/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066470"""
PDGFRA,P16234,D,842,V,"/note=""D -> V (in a GIST sample; imatinib resistant, constitutively activated kinase; dbSNP:rs121908585)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335, ECO:0000269|PubMed:20972453"" /id=""VAR_066471"""
PDGFRA,P16234,D,842,Y,"/note=""D -> Y (in a GIST sample; imatinib sensitive, constitutively activated kinase; dbSNP:rs121913265)"" /evidence=""ECO:0000269|PubMed:15928335"" /id=""VAR_066472"""
PDGFRA,P16234,H,845de,l,"/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066473"""
PDGFRA,P16234,D,846de,l,"/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066473"""
PDGFRA,P16234,S,847de,l,"/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066473"""
PDGFRA,P16234,N,848de,l,"/note=""Missing (in a GIST sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335"" /id=""VAR_066473"""
PDGFRA,P16234,Y,849,S,"/note=""Y -> S (in a hypereosinophilic syndrome sample; constitutively activated kinase)"" /evidence=""ECO:0000269|PubMed:21224473"" /id=""VAR_066475"""
PDGFRA,P16234,Y,572,F,"/note=""Y->F: Abolishes interaction with SRC-family members and impairs internalization of the activated receptor; when associated with F-574."" /evidence=""ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:14644164"""
PDGFRA,P16234,Y,574,F,"/note=""Y->F: Abolishes interaction with SRC-family members and impairs internalization of the activated receptor; when associated with F-572."" /evidence=""ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:14644164"""
KDR,P35968,C,482,R,"/note=""C -> R (in HCI; associated with disease susceptibility; expression of FLT1 in hemangioma endothelial cells is markedly reduced and KDR activity is increased compared to controls; low FLT1 expression in hemangioma cells is caused by reduced activity of a pathway involving ITGB1, ANTXR1, KDR and NFATC2IP; the mutation predicts to result in loss-of-function and disruption of the normal association of these molecules; dbSNP:rs34231037)"" /evidence=""ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18931684"" /id=""VAR_042057"""
